{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T22:08:48Z","timestamp":1792188528236,"version":"4.4.0"},"reference-count":46,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T00:00:00Z","timestamp":1758844800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.mdpi.com"],"crossmark-restriction":true},"short-container-title":["Life"],"abstract":"<jats:p>Clinical trials of drugs specifically targeting the sepsis response have frequently produced negative or inconclusive results. This has largely been due to the broad heterogeneity of enrolled patient populations, particularly when inclusion was based on the presence of the non-specific systemic inflammatory response syndrome (SIRS) criteria. The heterogeneity may have diluted any possible treatment effect: while some patients may have benefited from the intervention under investigation, others will have been harmed, resulting in an overall null-effect. Furthermore, an underlying infection is not always required for immune-modulating interventions to be effective; for example, patients with severe acute pancreatitis, but no infection, may still benefit from such therapies. There is therefore a need for better patient stratification or subphenotyping to identify those most likely to benefit from a particular therapy. Several trials have already adopted this approach using prognostic and\/or predictive enrichment strategies. For example, measurements of triggering receptor expressed on myeloid cells (TREM) could be used to identify candidates most likely to respond to anti-TREM therapies, or patients with coagulopathy or specific inflammatory patterns could be selected for treatments like thrombomodulin or activated protein C. However, challenges remain, including the need for more rapid tools that can be used at the bedside to inform real-time treatment decisions given the rapidly evolving nature of the sepsis response. Nevertheless, the era of broad-spectrum \u201csepsis drugs\u201d is now giving way to more selective, personalized interventions tailored to individual biological profiles, offering a more promising pathway for future therapeutic development\u2014even in the absence of infection.<\/jats:p>","DOI":"10.3390\/life15101517","type":"journal-article","created":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T11:28:32Z","timestamp":1758886112000},"page":"1517","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["The 15th Anniversary of Life\u2014Sepsis Trials"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6011-6951","authenticated-orcid":false,"given":"Jean-Louis","family":"Vincent","sequence":"first","affiliation":[{"name":"Department of Intensive Care, Erasme Hospital, H\u00f4pital Universitaire de Bruxelles (HUB), Universite Libre de Bruxelles (ULB), 1070 Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S0140-6736(19)32989-7","article-title":"Global, regional, and national sepsis incidence and mortality, 1990\u20132017: Analysis for the Global Burden of Disease Study","volume":"395","author":"Rudd","year":"2020","journal-title":"Lancet"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1056\/NEJM199102143240701","article-title":"Treatment of gram-negative bacteremia and septic shock with HA-1A human monoclonal antibody against endotoxin. A randomized, double-blind, placebo-controlled trial. The HA-1A Sepsis Study Group","volume":"324","author":"Ziegler","year":"1991","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1016\/S0140-6736(05)60602-2","article-title":"Double-blind randomised controlled trial of monoclonal antibody to human tumor necrosis factor in treatment of septic shock","volume":"351","author":"Abraham","year":"1998","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1001\/jama.1994.03510470040032","article-title":"Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome","volume":"271","author":"Fisher","year":"1994","journal-title":"JAMA"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/01.CCM.0000105581.01815.C6","article-title":"Multiple-center, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: Effect on survival in patients with septic shock","volume":"32","author":"Lopez","year":"2004","journal-title":"Crit. Care Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1056\/NEJMoa1202290","article-title":"Drotrecogin alfa (activated) in adults with septic shock","volume":"366","author":"Ranieri","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1378\/chest.101.6.1644","article-title":"Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis","volume":"101","author":"Bone","year":"1992","journal-title":"Chest"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1097\/01.CCM.0000050454.01978.3B","article-title":"2001 SCCM\/ESICM\/ACCP\/ATS\/SIS International Sepsis Definitions Conference","volume":"31","author":"Levy","year":"2003","journal-title":"Crit. Care Med."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Vincent, J.L., van der Poll, T., and Marshall, J.C. (2022). The end of \u201cone size fits all\u201d sepsis therapies: Toward an individualized approach. Biomedicines, 10.","DOI":"10.3390\/biomedicines10092260"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1164\/rccm.202311-2086SO","article-title":"From ICU syndromes to ICU subphenotypes: Consensus report and recommendations for developing precision medicine in the ICU","volume":"210","author":"Gordon","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_12","first-page":"2526","article-title":"Acute respiratory distress syndrome: The Berlin Definition","volume":"307","author":"Ranieri","year":"2012","journal-title":"JAMA"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1001\/jama.2019.5791","article-title":"Derivation, validation, and potential treatment implications of novel clinical phenotypes for sepsis","volume":"321","author":"Seymour","year":"2019","journal-title":"JAMA"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s13054-022-03972-8","article-title":"Identifying clinical subtypes in sepsis-survivors with different one-year outcomes: A secondary latent class analysis of the FROG-ICU cohort","volume":"26","author":"Soussi","year":"2022","journal-title":"Crit. Care"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1884","DOI":"10.1007\/s00134-024-07593-3","article-title":"Clinical phenotyping uncovers heterogeneous associations between corticosteroid treatment and survival in critically ill COVID-19 patients","volume":"50","author":"Bruse","year":"2024","journal-title":"Intensive Care Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1513\/AnnalsATS.202109-1088OC","article-title":"Clinical subtypes of sepsis survivors predict readmission and mortality after hospital discharge","volume":"19","author":"Taylor","year":"2022","journal-title":"Ann. Am. Thorac. Soc."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1186\/s13054-018-2279-3","article-title":"Identification of subclasses of sepsis that showed different clinical outcomes and responses to amount of fluid resuscitation: A latent profile analysis","volume":"22","author":"Zhang","year":"2018","journal-title":"Crit. Care"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1007\/s40121-022-00684-y","article-title":"Application of machine learning for clinical subphenotype identification in sepsis","volume":"11","author":"Hu","year":"2022","journal-title":"Infect. Dis. Ther."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/S2213-2600(16)00046-1","article-title":"Genomic landscape of the individual host response and outcomes in severe sepsis","volume":"4","author":"Davenport","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1164\/rccm.201807-1419OC","article-title":"Transcriptomic signatures in sepsis and a differential response to steroids: From the VANISH randomized trial","volume":"199","author":"Antcliffe","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/S2213-2600(17)30294-1","article-title":"Classification of patients with sepsis according to blood genomic endotype: A prospective cohort study","volume":"5","author":"Scicluna","year":"2017","journal-title":"Lancet Respir. Med."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1097\/CCM.0000000000003084","article-title":"Unsupervised analysis of transcriptomics in bacterial sepsis across multiple datasets reveals three robust clusters","volume":"46","author":"Sweeney","year":"2018","journal-title":"Crit. Care Med."},{"key":"ref_23","first-page":"e0478","article-title":"Plasma metabolites in early sepsis identify distinct clusters defined by plasma lipids","volume":"3","author":"Rogers","year":"2021","journal-title":"Crit. Care Explor."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00134-025-07859-4","article-title":"Metabolic septic shock sub-phenotypes, stability over time and association with clinical outcome","volume":"51","author":"Antcliffe","year":"2025","journal-title":"Intensive Care Med."},{"key":"ref_25","unstructured":"Food and Drug Administration (2025, August 27). Enrichment Strategies for Clinical Trials to Support Determination of Effectiveness of Human Drugs and Biological Products\u2014Guidance for Industry, Available online: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/enrichment-strategies-clinical-trials-support-approval-human-drugs-and-biological-products."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1038\/s41581-019-0199-3","article-title":"Prognostic and predictive enrichment in sepsis","volume":"16","author":"Stanski","year":"2020","journal-title":"Nat. Rev. Nephrol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.1097\/01.CCM.0000145229.59014.6C","article-title":"Efficacy and safety of the monoclonal anti-tumor necrosis factor antibody F(ab\u2032)2 fragment afelimomab in patients with severe sepsis and elevated interleukin-6 levels","volume":"32","author":"Panacek","year":"2004","journal-title":"Crit. Care Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1111\/anae.16314","article-title":"It ain\u2019t what you do (it\u2019s the way that you do it): Modulating the host response in sepsis","volume":"79","author":"Millar","year":"2024","journal-title":"Anaesthesia"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/s41591-022-01843-x","article-title":"Redefining critical illness","volume":"28","author":"Maslove","year":"2022","journal-title":"Nat. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1097\/CCM.0000000000005270","article-title":"Immune profiling demonstrates a common immune signature of delayed acquired immunodeficiency in patients with various etiologies of severe injury","volume":"50","author":"Venet","year":"2022","journal-title":"Crit. Care Med."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2581","DOI":"10.1084\/jem.20111354","article-title":"A genomic storm in critically injured humans","volume":"208","author":"Xiao","year":"2011","journal-title":"J. Exp. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e453","DOI":"10.1097\/SLA.0000000000003974","article-title":"Molecular patterns in acute pancreatitis reflect generalizable endotypes of the host response to systemic injury in humans","volume":"275","author":"Neyton","year":"2022","journal-title":"Ann. Surg."},{"key":"ref_33","doi-asserted-by":"crossref","unstructured":"Rios-Toro, J.J., Marquez-Coello, M., Garcia-Alvarez, J.M., Martin-Aspas, A., Rivera-Fernandez, R., Saez de Benito, A., and Giron-Gonzalez, J.A. (2017). Soluble membrane receptors, interleukin 6, procalcitonin and C reactive protein as prognostic markers in patients with severe sepsis and septic shock. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0175254"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/S2213-2600(23)00158-3","article-title":"Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): A double-blind, randomised, controlled, phase 2b trial","volume":"11","author":"Francois","year":"2023","journal-title":"Lancet Respir. Med."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1001\/jama.2019.5358","article-title":"Effect of a recombinant human soluble thrombomodulin on mortality in patients with sepsis-associated coagulopathy: The SCARLET randomized clinical trial","volume":"321","author":"Vincent","year":"2019","journal-title":"JAMA"},{"key":"ref_36","unstructured":"(2025, August 26). Spectral Medical and Vantive Announce Topline Results from Spectral\u2019s Tigris Trial Evaluating PMX Hemoadsorption Therapy for Endotoxic Septic Shock. Available online: https:\/\/www.vantive.com\/news\/press-releases\/spectral-medical-tigris-trial."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1007\/s00134-025-07873-6","article-title":"Sepsis subphenotypes, theragnostics and personalized sepsis care","volume":"51","author":"Antcliffe","year":"2025","journal-title":"Intensive Care Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/S2213-2600(23)00330-2","article-title":"Profiling the dysregulated immune response in sepsis: Overcoming challenges to achieve the goal of precision medicine","volume":"12","author":"Cajander","year":"2024","journal-title":"Lancet Respir. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s13054-025-05319-5","article-title":"An international observational study validating gene-expression sepsis immune subgroups","volume":"29","author":"Antcliffe","year":"2025","journal-title":"Crit. Care"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1164\/rccm.202406-1241OC","article-title":"Temporal transitions of the hyperinflammatory and hypoinflammatory phenotypes in critical illness","volume":"211","author":"Bartek","year":"2025","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.ccm.2024.08.005","article-title":"Precision medicine in acute respiratory distress syndrome: Progress, challenges, and the road ahead","volume":"45","author":"Leonard","year":"2024","journal-title":"Clin. Chest Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1186\/s13054-024-05202-9","article-title":"Urinary proteomics identifies distinct immunological profiles of sepsis associated AKI sub-phenotypes","volume":"28","author":"Stanaway","year":"2024","journal-title":"Crit. Care"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1164\/rccm.202401-0101CP","article-title":"The rise of adaptive platform trials in critical care","volume":"209","author":"Bos","year":"2024","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"S209","DOI":"10.1097\/01.CCM.0000126124.41743.86","article-title":"Endpoints in sepsis trials: More than just 28-day mortality?","volume":"32","author":"Vincent","year":"2004","journal-title":"Crit. Care Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1080\/17512433.2019.1643235","article-title":"Clinical trial design for unmet clinical needs: A spotlight on sepsis","volume":"12","author":"Vincent","year":"2019","journal-title":"Expert. Rev. Clin. Pharmacol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1186\/s13054-024-04964-6","article-title":"Towards personalized medicine: A scoping review of immunotherapy in sepsis","volume":"28","author":"Slim","year":"2024","journal-title":"Crit. Care"}],"container-title":["Life"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2075-1729\/15\/10\/1517\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,26]],"date-time":"2025-09-26T11:35:36Z","timestamp":1758886536000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2075-1729\/15\/10\/1517"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,26]]},"references-count":46,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["life15101517"],"URL":"https:\/\/doi.org\/10.3390\/life15101517","relation":{},"ISSN":["2075-1729"],"issn-type":[{"value":"2075-1729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,26]]}}}